Guenther G. Steger

13.0k total citations · 2 hit papers
156 papers, 6.0k citations indexed

About

Guenther G. Steger is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Guenther G. Steger has authored 156 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Oncology, 50 papers in Cancer Research and 49 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Guenther G. Steger's work include Cancer Treatment and Pharmacology (51 papers), HER2/EGFR in Cancer Research (44 papers) and Breast Cancer Treatment Studies (44 papers). Guenther G. Steger is often cited by papers focused on Cancer Treatment and Pharmacology (51 papers), HER2/EGFR in Cancer Research (44 papers) and Breast Cancer Treatment Studies (44 papers). Guenther G. Steger collaborates with scholars based in Austria, United States and Germany. Guenther G. Steger's co-authors include Rupert Bartsch, Michael Gnant, Christoph Zielinski, Allan Lipton, Katia Tonkin, Susie Jun, Michelle Fan, Jean-Jacques Body, Robert M. Mader and R. Jakesz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Guenther G. Steger

156 papers receiving 5.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

2010 1.1k citations Alison Stopeck, Allan Lipton et al. Journal of Clinical Oncology profile →
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

2010 700 citations Guenther G. Steger, Andrew Wardley et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guenther G. Steger Austria	34	4.6k	1.5k	1.3k	1.3k	1.1k	156	6.0k
Janine Mansi United Kingdom	41	3.5k 0.8×	2.3k 1.5×	1.2k 0.9×	1.0k 0.8×	798 0.7×	123	6.5k
Dimosthenis Skarlos Greece	31	4.9k 1.1×	2.1k 1.5×	873 0.7×	1.5k 1.2×	1.1k 1.0×	104	6.4k
Alain Lortholary France	30	3.0k 0.7×	801 0.5×	652 0.5×	682 0.5×	530 0.5×	169	4.1k
Philippe Beuzeboc France	47	3.9k 0.9×	3.2k 2.2×	2.4k 1.8×	1.2k 0.9×	1.4k 1.3×	243	7.6k
Aristotelis Bamias Greece	36	3.1k 0.7×	2.2k 1.5×	829 0.6×	1.7k 1.3×	471 0.4×	276	6.9k
Andrew Wardley United Kingdom	36	6.8k 1.5×	3.2k 2.1×	2.4k 1.8×	2.0k 1.6×	1.2k 1.1×	147	9.0k
Maciej Krzakowski Poland	43	7.6k 1.7×	6.4k 4.4×	1.6k 1.2×	2.2k 1.7×	785 0.7×	261	11.4k
Lee S. Rosen United States	50	8.4k 1.8×	3.8k 2.6×	1.1k 0.8×	3.6k 2.8×	1.7k 1.6×	232	12.1k
Sandy Srinivas United States	40	2.9k 0.6×	3.4k 2.3×	1.2k 0.9×	2.0k 1.5×	563 0.5×	192	6.6k
Umberto Basso Italy	35	2.1k 0.5×	1.7k 1.1×	736 0.5×	1.0k 0.8×	283 0.3×	236	4.7k

Countries citing papers authored by Guenther G. Steger

Since Specialization

Citations

This map shows the geographic impact of Guenther G. Steger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guenther G. Steger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guenther G. Steger more than expected).

Fields of papers citing papers by Guenther G. Steger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guenther G. Steger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guenther G. Steger. The network helps show where Guenther G. Steger may publish in the future.

Co-authorship network of co-authors of Guenther G. Steger

This figure shows the co-authorship network connecting the top 25 collaborators of Guenther G. Steger. A scholar is included among the top collaborators of Guenther G. Steger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guenther G. Steger. Guenther G. Steger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mackelenbergh, Marion van, Fenja Seither, Volker Möbus, et al.. (2022). Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer. 166. 185–201. 9 indexed citations

Steger, Guenther G., Daniel Egle, Rupert Bartsch, et al.. (2020). Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. The Breast. 50. 64–70. 13 indexed citations

Papakonstantinou, Andri, Alexios Matikas, Per Malmström, et al.. (2019). Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial. Cancer. 126(6). 1175–1182. 14 indexed citations

Bergen, Elisabeth, Anna S. Berghoff, Margaretha Rudas, et al.. (2019). Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. Clinical Cancer Research. 25(9). 2737–2744. 33 indexed citations

Singer, Christian F., Yen Y. Tan, Florian Fitzal, et al.. (2017). Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. Clinical Cancer Research. 23(14). 3676–3683. 32 indexed citations

Bergen, Elisabeth, Anna S. Berghoff, Peter Dubsky, et al.. (2016). Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Research and Treatment. 157(1). 91–99. 17 indexed citations

Steger, Guenther G., Michael Gnant, & Rupert Bartsch. (2015). Palbociclib for the treatment of postmenopausal breast cancer – an update. Expert Opinion on Pharmacotherapy. 17(2). 255–263. 15 indexed citations

Berghoff, Anna S., Rupert Bartsch, Matthias Preusser, et al.. (2014). Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. The Breast. 23(5). 637–643. 52 indexed citations

Berghoff, Anna S., Zsuzsanna Bagó-Horváth, Peter Dubsky, et al.. (2012). Brain metastases free survival differs between breast cancer subtypes. British Journal of Cancer. 106(3). 440–446. 68 indexed citations

10.

Bartsch, Rupert, Reinhard Ziebermayr, Christoph Zielinski, & Guenther G. Steger. (2010). Triple-negative breast cancer. Wiener Medizinische Wochenschrift. 160(7-8). 174–181. 56 indexed citations

11.

Stopeck, Alison, Allan Lipton, Jean-Jacques Body, et al.. (2010). Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. Journal of Clinical Oncology. 28(35). 5132–5139. 1102 indexed citations breakdown →

12.

Bartsch, Rupert, Guenther G. Steger, Michael Gnant, & Reinhard Ziebermayr. (2010). Breast Cancer: Rank Ligand Inhibition. Breast Care. 5(5). 320–325. 3 indexed citations

13.

Robertson, J.F.R., Guenther G. Steger, P. Neven, et al.. (2009). Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Annals of Oncology. 21(6). 1246–1253. 20 indexed citations

14.

Bartsch, Rupert, Catharina Wenzel, Christoph Zielinski, & Guenther G. Steger. (2007). HER-2-Positive Breast Cancer. BioDrugs. 21(2). 69–77. 31 indexed citations

15.

Steger, Guenther G., Sérgio D. Simon, Aňa Lluch, et al.. (2005). Fulvestrant (‘Faslodex’): Clinical experience from the Compassionate Use Programme. Cancer Treatment Reviews. 31. S10–S16. 18 indexed citations

16.

Wenzel, Catharina, Gottfried J. Locker, Rupert Bartsch, et al.. (2005). Preoperative second-line chemotherapy induces objective responses in primary breast cancer. Wiener klinische Wochenschrift. 117(1-2). 48–52. 4 indexed citations

17.

Steger, Guenther G., Robert M. Mader, Harald Vogelsang, et al.. (1994). Folate Absorption in Crohn’s Disease. Digestion. 55(4). 234–238. 9 indexed citations

18.

Mader, Robert M., et al.. (1994). Comparison of an Immunoradiometric and an Immunoluminometric Assay for the Evaluation of the Tumour Associated Antigens CA 19-9 and CA 125. Clinical Chemistry and Laboratory Medicine (CCLM). 32(2). 85–90. 1 indexed citations

19.

Heinz, R., Guenther G. Steger, Andreas Chott, et al.. (1992). MACOP-B treatment in patients with Ki-1-positive large-cell anaplastic lymphoma. Journal of Cancer Research and Clinical Oncology. 118(4). 314–317. 2 indexed citations

20.

Eichler, H.-G., H. Rainer, R. Jakesz, et al.. (1987). Phase-I Study of Intraperitoneal Mitoxantrone – Clinical and Pharmacokinetic Evaluation. Oncology Research and Treatment. 10(1). 54–56. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact